STOCK CAPITAL | NOTE 9:- STOCK CAPITAL a. Common Stock: Number of shares Authorized Issued and outstanding March 31, 2019 December 31, 2018 March 31, 2019 December 31, 2018 (unaudited) (unaudited) Stock of $0.0001 par value: Common stock 125,000,000 125,000,000 47,501,363 46,052,802 b. Stock Incentive plans: The Company’s 2007 Global Incentive Plan (the “2007 Plan”) was adopted by the board of directors on August 30, 2007. On March 31, 2015, once the Company completed its Initial Public Offering (“IPO”), the 2007 Plan was terminated and no further awards will be granted thereunder. All outstanding awards will continue to be governed by their existing terms and 379,358 available options for future grant were transferred to the Company’s 2015 Global Incentive Plan (the “2015 Plan”) and are reserved for future issuances under the 2015 plan. The 2015 Plan became effective upon the consummation of the IPO. The 2015 Plan provides for the grant of options, RSUs and other share-based awards to directors, employees, officers, and consultants of the Company and its Subsidiaries. As of March 31, 2019 (unaudited), a total of 10,383,357 shares of common stock were reserved for issuance under the 2015 Plan (the “Share Reserve”). The Share Reserve will automatically increase on January 1st of each year during the term of the 2015 Plan commencing on January 1st of the year following the year in which the 2015 Plan becomes effective in an amount equal to five percent (5%) of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year; provided, however, that our board of directors may determine that there will not be a January 1st increase in the Share Reserve in a given year or that the increase will be less than five percent (5%) of the shares of capital stock outstanding on the preceding December 31st. The aggregate maximum number of shares of common stock that may be issued on the exercise of incentive stock options is ten million (10,000,000). As of March 31, 2019 (unaudited), an aggregate of 8,686,589 shares of common stock are still available for future grant under the 2015 Plan. c. Options granted to employees A summary of the activity in the share options granted to employees and members of the board of directors for the three months ended March 31, 2019 (unaudited) and related information follows: Weighted average Weighted remaining Number average contractual Aggregate of exercise term intrinsic Options price in years Value Outstanding as of December 31, 2018 2,401,893 11.04 6.19 58,323 Granted 267,852 36.15 Exercised (25,512 ) 11.33 Forfeited or expired (10,625 ) 14.51 Outstanding as of March 31, 2019 2,633,608 13.58 6.33 63,544 Vested and expected to vest as of March 31, 2019 2,592,033 13.44 6.30 62,901 Exercisable as of March 31, 2019 1,896,037 8.32 5.46 55,675 The aggregate intrinsic value represents the total intrinsic value (the difference between the fair value of the Company’s common stock as of the last day of each period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on the last day of each period. The total intrinsic value of options exercised during the three months ended March 31, 2019 (unaudited) was $788. The weighted average grant date fair values of options granted to employees and executive directors during the three months ended March 31, 2019 (unaudited) was $19.83. d. Number of RSUs Weighted average fair value Unvested as of December 31, 2018 2,807,232 34.40 Granted 306,562 38.55 Vested (223,210 ) 31.14 Forfeited (96,018 ) 33.91 Unvested as of 2,794,566 35.13 As part of SMRE acquisition, the Company granted 334,096 PSUs that are subject to certain performance goals and a vesting period. The PSUs grant date fair value is $40.24. During the three months ended March 31, 2019, the Company recognized expenses at the amount of $841 related to PSU’S vesting that were expensed in the condensed consolidated statement of operations in general and administrative expenses line item. e. Options and RSUs issued to non-employee consultants: The Company has granted options and RSUs to purchase common shares to non-employee consultants as of March 31, 2019 (unaudited) as follows: Outstanding Exercisable as of as of Issuance March 31, Exercise March 31, Options exercisable Date 2019 price 2019 through 2014 6,023 $3.51 - $5.01 5,245 October 29, 2024 2015 2,127 $0.00 - 2016 5,001 $0.00 - $15.34 - September 21, 2026 2017 13,126 $0.00 - $13.70 - March 15, 2027 2018 19,496 $0.00 - 2019 9,499 $0.00 - 55,272 5,245 The Company had accounted for its options and RSUs granted to non-employee consultants under the fair value method of ASC 505-50 (“Equity-Based Payments to Non-Employees”). In connection with the grant of stock options and RSUs to non‑employee consultants, the Company recorded stock compensation expenses in the three months ended March 31, 2019 (unaudited) and 2018 (unaudited) in the amount of $173 and $ 529, respectively. f. Employee Stock Purchase Plan (“ESPP”): The Company adopted an Employee Stock Purchase Plan (the “ESPP”) effective upon the consummation of the IPO. As of March 31, 2019 (unaudited), a total of 2,199,808 shares were reserved for issuance under this plan. The number of shares of common stock reserved for issuance under the ESPP will increase automatically on January 1st of each year, for ten years, by the lesser of 1% of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or 487,643 shares. However, the Company’s board of directors may reduce the amount of the increase in any particular year at their discretion, including a reduction to zero. The ESPP is implemented through an offering every six months. According to the ESPP, eligible employees may use up to 10% of their salaries to purchase common stock shares up to an aggregate limit of $10 per participant for every six months plan. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the subscription date of each offering period or on the purchase date. As of March 31, 2019 (unaudited), 385,646 common stock shares had been purchased under the ESPP. As of March 31, 2019 (unaudited), 1,814,162 common stock shares were available for future issuance under the ESPP. In accordance with ASC No. 718, the ESPP is compensatory and as such results in recognition of compensation cost. g. Stock-based compensation expense for employees and non-employee consultants: The Company recognized stock-based compensation expenses related to stock options, RSUs and PSUs granted to employees and non-employee consultants and ESPP in the condensed consolidated statement of income for the three months ended March 31, 2019 (unaudited) and 2018 (unaudited), as follows: Three months ended March 31, 2019 2018 Cost of revenues $ 1,354 $ 924 Research and development 3,490 2,382 Selling and marketing 2,404 2,204 General and administrative 2,456 1,339 Total stock-based compensation expense $ 9,704 $ 6,849 As of March 31, 2019 (unaudited), there was a total unrecognized compensation expense of $104,122 related to non‑vested equity‑based compensation arrangements granted under the Company’s Plans. These expenses are expected to be recognized during the period from April 1, 2019 through May 31, 2023. |